A detailed history of Jim Simons (Renaissance Technologies LLC) transactions in Aclaris Therapeutics, Inc. stock. As of the latest transaction made, Renaissance Technologies LLC holds 1,370,700 shares of ACRS stock, worth $2.81 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,370,700
Previous 922,200 48.63%
Holding current value
$2.81 Million
Previous $1.01 Million 52.66%
% of portfolio
0.0%
Previous 0.0%

Shares

24 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$1.12 - $1.4 $502,320 - $627,900
448,500 Added 48.63%
1,370,700 $1.55 Million
Q2 2024

Aug 09, 2024

SELL
$1.01 - $1.36 $758,712 - $1.02 Million
-751,200 Reduced 44.89%
922,200 $1.01 Million
Q1 2024

May 13, 2024

SELL
$0.92 - $1.44 $67,189 - $105,166
-73,032 Reduced 4.18%
1,673,400 $2.08 Million
Q4 2023

Feb 13, 2024

BUY
$0.64 - $6.49 $703,219 - $7.13 Million
1,098,780 Added 169.66%
1,746,432 $1.83 Million
Q3 2023

Nov 14, 2023

SELL
$6.56 - $10.95 $2.11 Million - $3.52 Million
-321,900 Reduced 33.2%
647,652 $4.44 Million
Q2 2023

Aug 11, 2023

SELL
$7.89 - $10.64 $2.23 Million - $3.01 Million
-282,600 Reduced 22.57%
969,552 $10.1 Million
Q1 2023

May 12, 2023

BUY
$7.07 - $17.95 $921,928 - $2.34 Million
130,400 Added 11.62%
1,252,152 $10.1 Million
Q4 2022

Feb 13, 2023

SELL
$14.33 - $18.37 $908,894 - $1.17 Million
-63,426 Reduced 5.35%
1,121,752 $17.7 Million
Q3 2022

Nov 14, 2022

SELL
$13.07 - $18.22 $1.89 Million - $2.63 Million
-144,500 Reduced 10.87%
1,185,178 $18.7 Million
Q2 2022

Aug 12, 2022

SELL
$10.16 - $17.08 $1.3 Million - $2.18 Million
-127,900 Reduced 8.77%
1,329,678 $18.6 Million
Q1 2022

May 13, 2022

SELL
$9.74 - $17.92 $2.14 Million - $3.93 Million
-219,300 Reduced 13.08%
1,457,578 $25.1 Million
Q4 2021

Feb 11, 2022

SELL
$12.27 - $18.49 $4.22 Million - $6.36 Million
-344,000 Reduced 17.02%
1,676,878 $24.4 Million
Q3 2021

Nov 12, 2021

SELL
$13.38 - $18.8 $5.5 Million - $7.73 Million
-411,000 Reduced 16.9%
2,020,878 $36.4 Million
Q2 2021

Aug 13, 2021

SELL
$17.08 - $29.6 $9.47 Million - $16.4 Million
-554,600 Reduced 18.57%
2,431,878 $42.7 Million
Q1 2021

May 13, 2021

SELL
$5.86 - $27.73 $1.65 Million - $7.81 Million
-281,700 Reduced 8.62%
2,986,478 $75.3 Million
Q4 2020

Feb 10, 2021

SELL
$2.65 - $7.61 $437,811 - $1.26 Million
-165,212 Reduced 4.81%
3,268,178 $21.1 Million
Q3 2020

Nov 13, 2020

BUY
$1.5 - $2.71 $230,325 - $416,120
153,550 Added 4.68%
3,433,390 $8.82 Million
Q2 2020

Aug 13, 2020

BUY
$1.04 - $1.73 $108,372 - $180,272
104,204 Added 3.28%
3,279,840 $5.31 Million
Q1 2020

May 14, 2020

BUY
$0.75 - $2.18 $295,004 - $857,479
393,339 Added 14.14%
3,175,636 $3.3 Million
Q4 2019

Feb 13, 2020

BUY
$1.02 - $1.97 $829,852 - $1.6 Million
813,581 Added 41.33%
2,782,297 $5.26 Million
Q3 2019

Nov 13, 2019

BUY
$0.79 - $2.47 $1 Million - $3.13 Million
1,269,136 Added 181.41%
1,968,716 $2.13 Million
Q2 2019

Aug 12, 2019

BUY
$2.13 - $7.06 $579,786 - $1.92 Million
272,200 Added 63.69%
699,580 $1.53 Million
Q1 2019

May 14, 2019

BUY
$5.63 - $7.84 $1.87 Million - $2.6 Million
331,700 Added 346.68%
427,380 $2.56 Million
Q4 2018

Feb 13, 2019

BUY
$6.3 - $15.4 $602,784 - $1.47 Million
95,680 New
95,680 $707,000

Others Institutions Holding ACRS

About Aclaris Therapeutics, Inc.


  • Ticker ACRS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Diagnostics & Research
  • Shares Outstandng 66,671,800
  • Market Cap $137M
  • Description
  • Aclaris Therapeutics, Inc. operates a clinical-stage biopharmaceutical company, develops novel drug candidates for immune-inflammatory diseases in the United States. It operates through two segments: Therapeutics and Contract Research. The Therapeutics segment is involved in identifying and developing innovative therapies to address significant ...
More about ACRS
Track Jim Simons's Portfolio

Track Jim Simons Portfolio

Follow Jim Simons (Renaissance Technologies LLC) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Renaissance Technologies LLC, based on Form 13F filings with the SEC.

News

Stay updated on Renaissance Technologies LLC and Jim Simons with notifications on news.